SCHEMBL19686705

SCHEMBL19686705

Cc1ccn(-c2nc(NC3CCC(N(C)C)CC3)cc(N3CCOCC3)n2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
LMNA P02545 3/20 0.39
HPGD P15428 1/20 0.39
PIK3CA P42336 3/20 0.39
MTOR P42345 1/20 0.39
PDE10A Q9Y233 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.38
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
APAF1 O14727 1/20 0.38
CHRM3 P20309 2/20 0.37
PDE4A P27815 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686381 0.89 ADORA2A (0.43) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686709 0.88 ADORA2A (0.42) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686702 0.88 PIK3CA (0.51) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL21578586 0.88 HRH4 (0.44) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686717 0.86 ADORA2A (0.41) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686704 0.86 ADORA2A (0.41) KDM4EKMT2AMAPTMEN1ALDH1A1
Rimtuzalcap SCHEMBL29920754 0.85 IDH1 (0.43) KDM4EKMT2AMAPTMEN1ALDH1A1
Rimtuzalcap SCHEMBL19686931 0.85 IDH1 (0.43) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686716 0.84 ADORA2A (0.46) KDM4EKMT2AMAPTMEN1ALDH1A1
SCHEMBL19686708 0.84 ADORA2A (0.46) KDM4EKMT2AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KDM4E 1648/4885KMT2A 1471/4885MAPT 2009/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KDM4E 1648/4885KMT2A 1471/4885MAPT 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.